Patents by Inventor Rita Dost

Rita Dost has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Triazoles as NR2B receptor inhibitors
    Patent number: 10323021
    Abstract: Provided here in are compounds of Formula I having the structure: Also provided herein are compositions comprising compounds of Formula I and methods of using compounds of Formula I for the treatment of disorders, diseases or conditions mediated by GluN2B receptors.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: June 18, 2019
    Assignee: JANSSEN PHARMACEUTICALS, INC.
    Inventors: Rudolf Schindler, Hans-Joachim Lankau, Norbert Höfgen, Ute Egerland, Barbara Langen, Rita Dost, Simon Ward
  • Pyrazoles
    Patent number: 10155727
    Abstract: The invention relates to pyrazole derivatives which are NMDA NR2B receptor inhibitors, useful in treating central nervous system diseases.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: December 18, 2018
    Assignee: JANSSEN PHARMACEUTICALS, INC.
    Inventors: Rudolf Schindler, Hans-Joachim Lankau, Norbert Höfgen, Christian Grunwald, Ute Egerland, Barbara Langen, Rita Dost, Thorsten Hage, Simon Ward
  • TRIAZOLES AS NR2B RECEPTOR INHIBITORS
    Publication number: 20180282305
    Abstract: Provided here in are compounds of Formula I having the structure: Also provided herein are compositions comprising compounds of Formula I and methods of using compounds of Formula I for the treatment of disorders, diseases or conditions mediated by GluN2B receptors.
    Type: Application
    Filed: April 27, 2018
    Publication date: October 4, 2018
    Inventors: Rudolf Schindler, Hans-Joachim Lankau, Norbert Höfgen, Ute Egerland, Barbara Langen, Rita Dost, Simon Ward
  • Triazoles as NR2B receptor inhibitors
    Patent number: 9981950
    Abstract: Provided here in are compounds of Formula I having the structure: Also provided herein are compositions comprising compounds of Formula I and methods of using compounds of Formula I for the treatment of disorders, diseases or conditions mediated by GluN2B receptors.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: May 29, 2018
    Assignee: JANSSEN PHARMACEUTICALS, INC.
    Inventors: Rudolf Schindler, Hans-Joachim Lankau, Norbert Höfgen, Ute Egerland, Barbara Langen, Rita Dost, Simon Ward
  • PYRAZOLES
    Publication number: 20170275254
    Abstract: The invention relates to pyrazole derivatives which are NMDA NR2B receptor inhibitors, useful in treating central nervous system diseases.
    Type: Application
    Filed: August 14, 2015
    Publication date: September 28, 2017
    Inventors: Rudolf Schindler, Hans-Joachim Lankau, Norbert Höfgen, Christian Grunwald, Ute Egerland, Barbara Langen, Rita Dost, Thorsten Hage, Simon Ward
  • TRIAZOLES AS NR2B RECEPTOR INHIBITORS
    Publication number: 20170226087
    Abstract: Provided here in are compounds of Formula I having the structure: Also provided herein are compositions comprising compounds of Formula I and methods of using compounds of Formula I for the treatment of disorders, diseases or conditions mediated by GluN2B receptors.
    Type: Application
    Filed: August 14, 2015
    Publication date: August 10, 2017
    Inventors: Rudolf Schindler, Hans-Joachim Lankau, Norbert Höfgen, Ute Egerland, Barbara Langen, Rita Dost, Simon Ward
  • (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
    Patent number: 9540379
    Abstract: The invention relates to (1,2,4)triazolo[4,3-a]quinoxaline derivatives which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: January 10, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Hans-Joachim Lankau, Barbara Langen, Christian Grunwald, Norbert Hoefgen, Hans Stange, Rita Dost, Ure Egerland
  • USE OF DIHYDROIMIDAZOLONES FOR THE TREATMENT OF DOGS
    Publication number: 20160367562
    Abstract: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.
    Type: Application
    Filed: August 30, 2016
    Publication date: December 22, 2016
    Inventors: Chris RUNDFELDT, Rita DOST, Wolfgang LOSCHER, Andrea TIPOLD, Klaus UNVERFERTH, Hans-Joachim LANKAU
  • Use of dihydroimidazolones for the treatment of dogs
    Patent number: 9469611
    Abstract: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: October 18, 2016
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Chris Rundfeldt, Rita Dost, Wolfgang Loscher, Andrea Tipold, Klaus Unverferth, Hans-Joachim Lankau
  • USE OF DIHYDROIMIDAZOLONES FOR THE TREATMENT OF DOGS
    Publication number: 20150072983
    Abstract: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.
    Type: Application
    Filed: November 17, 2014
    Publication date: March 12, 2015
    Inventors: Chris RUNDFELDT, Rita DOST, Wolfgang LOSCHER, Andrea TIPOLD, Klaus UNVERFERTH, Hans-Joachim LANKAU
  • Use of dihydroimidazolones for the treatment of dogs
    Patent number: 8962617
    Abstract: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: February 24, 2015
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Chris Rundfeldt, Rita Dost, Wolfgang Loscher, Andrea Tipold, Klaus Unverferth, Hans-Joachim Lankau
  • Use of dihydroimidazolones for the treatment of dogs
    Patent number: 8859540
    Abstract: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: October 14, 2014
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Chris Rundfeldt, Rita Dost, Wolfgang Loscher, Andrea Tipold, Klaus Unverferth, Hans-Joachim Lankau
  • USE OF DIHYDROIMIDAZOLONES FOR THE TREATMENT OF DOGS
    Publication number: 20130065898
    Abstract: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 14, 2013
    Inventors: CHRIS RUNDFELDT, Rita Dost, Wolfgang Loscher, Andrea Tipold, Klaus Unyerferth, Hans-Joachim Lankau
  • (1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES
    Publication number: 20120302564
    Abstract: The invention relates to (1,2,4)triazolo[4,3-a]quinoxaline derivatives which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases.
    Type: Application
    Filed: January 30, 2012
    Publication date: November 29, 2012
    Inventors: Hans-Joachim Lankau, Barbara Langen, Christian Grunwald, Norbert Hoefgen, Hans Stange, Rita Dost, Ure Egerland
  • Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor
    Publication number: 20080114032
    Abstract: The present invention relates to the use of 1-ar(alk)ylimidazolin-2-ones which contain a disubstituted amine radical in the 4-position for the treatment or prevention of central nervous system disorders including depression, anxiety, movement disorders, and especially dystonia, and psychotic disorders, and especially schizophrenia and psychotic symptoms associated to other mental disorders.
    Type: Application
    Filed: October 29, 2007
    Publication date: May 15, 2008
    Inventors: Barbara Langen, Chris Rundfeldt, Rita Dost, Hartmut Luddens, Holger Rabe
  • Use of dihydroimidazolones for the treatment of dogs
    Publication number: 20080027057
    Abstract: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1 H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.
    Type: Application
    Filed: July 18, 2007
    Publication date: January 31, 2008
    Inventors: Chris Rundfeldt, Rita Dost, Wolfgang Loscher, Andrea Tipold, Klaus Unverferth, Hans-Joachim Lankau
  • Use of dihydroimidazolones for the treatment of dogs
    Publication number: 20050070537
    Abstract: The present invention relates to the use of substituted dihydroimidazolones, particularly [1-(4-Chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol-2-one] (AWD 131-138) or a physiologically acceptable salt thereof for the treatment of epilepsy in dogs.
    Type: Application
    Filed: October 6, 2003
    Publication date: March 31, 2005
    Inventors: Chris Rundfeldt, Rita Dost, Wolfgang Loscher, Andrea Tipold, Klaus Unverferth, Hans-Joachim Lankau
  • Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor
    Publication number: 20050032863
    Abstract: The present invention relates to the use of 1-ar(alk)ylimidazolin-2-ones which contain a disubstituted amine radical in the 4-position for the treatment or prevention of central nervous system disorders including depression, anxiety, movement disorders, and especially dystonia, and psychotic disorders, and especially schizophrenia and psychotic symptoms associated to other mental disorders.
    Type: Application
    Filed: June 28, 2004
    Publication date: February 10, 2005
    Inventors: Barbara Langen, Chris Rundfeldt, Rita Dost, Hartmut Luddens, Holger Rabe
  • 2,5-Dihydro-pyrazolo[3,4-d]pyrimidin-4-ones with an anticonsulsive action and methods for producing the same
    Publication number: 20030186997
    Abstract: The invention relates to 2,5-dihydropyrazolo[3,4-d]pyrimidin-4-ones and their tautomers which contain in the 5-position an ar(alkyl) radical and in the 2-position a hydrogen or an ar(alkyl) radical, processes for their preparation and their use as medicaments, in particular for the treatment of epilepsy of various forms.
    Type: Application
    Filed: February 18, 2003
    Publication date: October 2, 2003
    Inventors: Thomas Arnold, Hans-Joachim Lankau, Klaus Unverferth, Christine Tober, Chris Rundfeldt, Rita Dost, Katrin Bernoster, Antje Gasparic
  • Pyrazoles
    Patent number: RE49517
    Abstract: The invention relates to pyrazole derivatives which are NMDA NR2B receptor inhibitors, useful in treating central nervous system diseases.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: May 2, 2023
    Assignee: JANSSEN PHARMACEUTICALS, INC.
    Inventors: Rudolf Schindler, Hans-Joachim Lankau, Norbert Höfgen, Christian Grunwald, Ute Egerland, Barbara Langen, Rita Dost, Thorsten Hage, Simon Ward